Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook
Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.
Reuters4d
Merck plans to launch US subcutaneous version of Keytruda on October 1
NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...
CURE6d
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
Pharmabiz3d
Immutep doses first patient in its TACTI-004 phase III clinical trial in first line non-small cell lung cancer
Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...
FiercePharma4d
Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme
Keytruda SC also showed a safety profile that’s consistent with IV. Grade 3 or above treatment-related adverse events happened in 47% of patients who received the under-the-skin version and ...
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated ...
Seeking Alpha5d
Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook
Keytruda earned $29.5bn of revenues in 2024 ... This prevents competing therapies with a similar mechanism of action (“MoA”) from being launched and challenging for market share, and also ...
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...
Yahoo Finance6d
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
The anti-cancer immune response driven by efti’s unique mechanism of action as an MHC Class II agonist in combination with KEYTRUDA has led to strong efficacy across all PD-L1 levels with ...